Article citationsMore>>

Attallah, A.M., Shiha, G.E., Ismail, H., Mansy, S.E., El-Sherbiny, R. and El-Dosoky, I. (2009) Expression of p53 Protein in Liver and Sera of Patients with Liver Fibrosis, Liver Cirrhosis or Hepatocellular Carcinoma Associated with Chronic HCV Infection. Clinical Biochemistry, 42, 455-461.
https://doi.org/10.1016/j.clinbiochem.2008.11.004

has been cited by the following article:

• TITLE: Impact of the Hepatitis B Virus pRE-S2 Mutant on p53 and PLK1 Biomarkers Expression in Patients with Hepatocellular Carcinoma in Brazzaville

  AUTHORS: Luc Magloire Anicet Boumba, Clausina Ahoui Mikolele, Dimitri Moudiongui Mboungou Malanda, Ghislain Lobano-Voumbi, Bredin Bissila, Josué Lukera Chimaëlle Biziki Batsimba, Paola Candyse Tsimba, Blaise Irenée Atipo Ibara, Donatien Moukassa

  KEYWORDS: Hepatocellular Carcinoma, Hepatitis B Virus, pRE-S2 Mutant, p53 and PLK1 Biomarkers, Congo

  JOURNAL NAME: Advances in Infectious Diseases, Vol.15 No.4, November 6, 2025

  ABSTRACT: Hepatocellular carcinoma (HCC) is the most common primary liver tumor and a major public health problem, particularly in sub-Saharan Africa. Hepatitis B virus (HBV) is an important etiological factor, and its mutants, particularly pRE-S2, are associated with an increased risk of HCC. To evaluate the impact of the HBV pRE-S2 mutant on the expression of p53 and PLK1 biomarkers in patients with HCC in Brazzaville. A case-control analytical study was conducted between July and December 2024, i.e., 6 months, including 82 participants divided into two groups: 22 patients with HBV-related HCC (cases) and 60 controls, including 30 controls infected with HBV without HCC (sick controls) and 30 healthy control subjects. Serum expression of pRE-S2, p53, and PLK1 was analyzed by ELISA. Data were processed by GraphPad Prism with a significance threshold of p